UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035185
Receipt number R000040100
Scientific Title The study of the combination effect of granulocyte/monocyte adsorptive apheresis in Crohn's disease patients who lose response to Infliximab therapy
Date of disclosure of the study information 2019/04/01
Last modified on 2023/12/12 13:33:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of the combination effect of granulocyte/monocyte adsorptive apheresis in Crohn's disease patients who lose response to Infliximab therapy

Acronym

The study of the combination effect of GMA in Crohn's disease patients who lose response to Infliximab therapy

Scientific Title

The study of the combination effect of granulocyte/monocyte adsorptive apheresis in Crohn's disease patients who lose response to Infliximab therapy

Scientific Title:Acronym

The study of the combination effect of GMA in Crohn's disease patients who lose response to Infliximab therapy

Region

Japan


Condition

Condition

Crohn's disease

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of Granulocyte/ Monocyte Adsorption apheresis (GMA) for Crohn's disease patients who lose response to infliximab therapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The rate of clinical response (improvement of CDAI score more than 70 points) at week 16

Key secondary outcomes

(1) Remission (CDAI<150) rate at week 16
(2) Change of blood lebel of IFX
(3) Change of antibody to infliximab(ATI)
(4) Change in CRP
(5) Safety assessment


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

17 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Crohn's disease patients with maintenance IFX therapy
(2) Patients with CDAI score of 220 to 450 points or serum CRP of more than 0.3mg/dl
(3) Patients considered being capable for venous catheter insertion

Key exclusion criteria

(1) Adacolumn contraindication
(2) Other patients judged as inappropriate by the physician

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Junji
Middle name
Last name Yokoyama

Organization

Niigata University Medical and Dental Hospital

Division name

Division of endoscopy

Zip code

951-8510

Address

1-754 Asahimachidori, Chuo-ku, niigata city

TEL

025-227-2207

Email

yokoyaj@med.niigata-u.ac.jp


Public contact

Name of contact person

1st name Junji
Middle name
Last name Yokoyama

Organization

Niigata University Medical and Dental Hospital

Division name

Division of endoscopy

Zip code

951-8510

Address

1-754 Asahimachidori, Chuo-ku, niigata city

TEL

025-227-2207

Homepage URL


Email

yokoyaj@med.niigata-u.ac.jp


Sponsor or person

Institute

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Niigata University ethic screening committee

Address

1-754 Asahimachidori, Chuo-ku, niigata city

Tel

025-227-2625

Email

https://niigata.bvits.com/rinri/


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 11 Month 28 Day

Date of IRB

2017 Year 12 Month 01 Day

Anticipated trial start date

2018 Year 04 Month 01 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

prospective observational study


Management information

Registered date

2018 Year 12 Month 08 Day

Last modified on

2023 Year 12 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040100


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name